Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;72(10):2097-2111.
doi: 10.1002/iub.2356. Epub 2020 Aug 8.

Bacterial co-infections with SARS-CoV-2

Affiliations
Review

Bacterial co-infections with SARS-CoV-2

Rasoul Mirzaei et al. IUBMB Life. 2020 Oct.

Abstract

The pandemic coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID-19 are underway. Respiratory viral infections, such as influenza, predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS-CoV-2). Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.

Keywords: COVID-19; SARS-CoV-2; antibiotic; bacterial co-infection; viral infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Postulated schematic of bacterial coinfection with SARS‐CoV‐2 infection. It has been proposed when SARS‐ CoV‐2 infects lung cells can damage the cells and the lung infrastructure. This situation attracts neutrophil and macrophages to the site of infection and promoting the inflammation. Finally, the changed situation and epithelial damage can cause bacteria to adhere to and invasion of the cells and proliferation. MQ, macrophage; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2

Similar articles

Cited by

References

    1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473. - PMC - PubMed
    1. Organization T.W.H . Coronavirus disease (COVID‐19) pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Zimmermann P, Curtis N. Coronavirus infections in children including COVID‐19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355. - PMC - PubMed
    1. McArdle AJ, Turkova A, Cunnington AJ. When do co‐infections matter? Curr Opin Infect Dis. 2018;31:209. - PMC - PubMed
    1. Paget C, Trottein F. Mechanisms of bacterial superinfection post‐influenza: A role for unconventional T cells. Front Immunol. 2019;10:336–336. - PMC - PubMed

MeSH terms